Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), James Larkin(Trinity College Dublin), Ana Arance(Hospital Clínic de Barcelona), Luis de la Cruz‐Merino, Andrew F. Hill(National Center for Emerging and Zoonotic Infectious Diseases), Leslie A. Fecher(University of Pennsylvania), Michael Schenker(Sorbonne Université), Devanand Joseph(Bristol-Myers Squibb (United States)), Barbara Merelli(Ospedale Papa Giovanni XXIII), Melanie Pe Benito(Bristol-Myers Squibb (United States)), Petr Arenberger(Charles University), Paul C. Nathan(University of Toronto), Caroline Gaudy‐Marqueste(Aix-Marseille Université), Charles Lance Cowey(Baylor University), Jacopo Pigozzo(Istituto Oncologico Veneto), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), Margarita Askelson(Bristol-Myers Squibb (United States)), Michael Millward(The University of Western Australia), Raheela Soomro(Bristol-Myers Squibb (United States)), Oleg Gligich, Helen Gogas(National and Kapodistrian University of Athens), Victoria Atkinson(Greenslopes Private Hospital), Anna Maria Di Giacomo(University of Siena), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Dhanrajsinh Rathod(Bristol-Myers Squibb (United States)), Marcus O. Butler(University of Toronto)
Cited by 21
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k